Table 2.
Clinical studies evaluating drugs that target cancer metabolism
| Target | Drugs | Cancer | Clinical Trials | Status | ID |
|---|---|---|---|---|---|
| GLS1 | CB-839 | Advanced cervical cancer | Phase I | Active | NCT05521997 |
| GLS1 | CB-839 | Specific genetic mutations and solid tumors or malignant peripheral nerve sheath tumors | Phase II | Active | NCT03872427 |
| GLS1 | CB-839 | Prostate cancer | Phase II | Active | NCT04824937 |
| GLS1 | CB-839 | Recurrent or refractory multiple myeloma | Phase I | Active | NCT03798678 |
| GLS1 | CB-839 | IDH-mutated diffuse astrocytoma or anaplastic astrocytoma | Phase Ib | Active | NCT03528642 |
| PDH/α-KGDH | CPI-613 | Leukemia, lymphoma | phase II | Active | NCT03793140 |
| PDH/α-KGDH | CPI-613 | Pancreatic cancer | Phase I/II | Active | NCT03699319 |
| PDH/α-KGDH | CPI-613 | Biliary tract cancer | Phase I/II | Active | NCT04203160 |
| OXPHOS | Metformin | Malignant glioma | Phase II | Active | NCT04945148 |
| OXPHOS | ME-344 | Previously treated metastatic colorectal cancer | Phase Ib | Active | NCT05824559 |
| FASN | TVB-2640 | Colon and other resectable cancers | Phase I | Active | NCT02980029 |
| FASN | TVB-2640 | Castration-resistant prostatic neoplasms, | Phase I | Active | NCT05743621 |
| FASN | Omeprazole | Prostate cancer, refractory Cancer, castration resistant prostatic cancer | Phase II | Active | NCT04337580 |
| LAT1 | IAG933 | Mesothelioma | Phase I | Active | NCT04857372 |
| LAT1 | JPH203 | Advanced biliary tract cancers | Phase II | Active | JPRN-UMIN000034080 |